Sage’s seizure drug fails key trial, shares slump

Print pagePDF pageEmail page

(Reuters) – Sage Therapeutics Inc’s shares tumbled 23 percent on Tuesday after its drug to treat a life-threatening seizure disorder failed to meet the main goal of a key trial, raising concerns about the future of the study.


Reuters: Health News … More ادامه مطلب

Leave a Reply

Time limit is exhausted. Please reload CAPTCHA.